Allogene Therapeutics (ALLO) Deferred Taxes (2018 - 2019)

Allogene Therapeutics' (ALLO) quarterly Deferred Taxes came in at $33000.0 in Q3 2019, up 120.75% quarter-over-quarter from -$159000.0 in Q2 2019.

Allogene Therapeutics (ALLO) Deferred Taxes (2018 - 2019) Analysis & Trends

Allogene Therapeutics has disclosed Deferred Taxes across 2 years of filings, most recently posting $33000.0 for Q3 2019.

Deferred Taxes for Q3 2019 came in at $33000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2020 was $33000.0 (down 99.92% YoY), and the FY2018 annual result was $41.9 million, changed N/A from the prior year.
Deferred Taxes came in at $33000.0 for Q3 2019 at Allogene Therapeutics, up from -$159000.0 in the prior quarter.
In the past five years, Deferred Taxes ranged from a high of $41.9 million in Q4 2018 to a low of -$159000.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-859,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-65.30 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Allogene Therapeutics	482.98 Mn	482.98 Mn	-	-

Download Data